Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
Top Cited Papers
- 1 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 25 (5) , 951-958
- https://doi.org/10.1097/hjh.0b013e3280bad9b4
Abstract
To evaluate the blood pressure-dependent and independent effects of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on major cardiovascular events. Using data from 26 large-scale trials comparing an ACEI or an ARB with placebo or another drug class, meta-regression analyses were conducted in which treatment-specific relative risks for major cause-specific outcomes [stroke, major coronary heart disease (CHD) events and heart failure] were regressed against follow-up blood pressure differences. From a total of 146 838 individuals with high blood pressure or an elevated risk of cardiovascular disease, 22 666 major cardiovascular events were documented during follow-up. The analyses showed comparable blood pressure-dependent reductions in risk with ACEI and ARB (P ≥ 0.3 for all three outcomes). The analyses also showed that ACEI produced a blood pressure-independent reduction in the relative risk of CHD of approximately 9% (95% confidence interval 3–14%). No similar effect was detected for ARB, and there was some evidence of a difference between ACEI and ARB in this regard (P = 0.002). For both stroke and heart failure there was no evidence of any blood pressure-independent effects of either ACEI or ARB. There are similar blood pressure-dependent effects of ACEI and ARB for the risks of stroke, CHD and heart failure. For ACEI, but not ARB, there is evidence of blood pressure-independent effects on the risk of major coronary disease events.Keywords
This publication has 43 references indexed in Scilit:
- Recent hypertension trials: Implications and controversiesJournal of the American College of Cardiology, 2005
- Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood PressureJAMA, 2004
- Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)BMJ, 2004
- Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsThe Lancet, 2003
- Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)The Lancet, 2003
- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeThe Lancet, 2003
- Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trialThe Lancet, 2002
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololPublished by Elsevier ,2002
- Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE IIThe Lancet, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000